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Methods: Beginning in June, 2011, we invited all surviving ARIC participants to undergo cognitive,
neurologic, and brain imaging assessments to diagnose MCI or dementia and assign an etiology for
the cognitive disorder.
Results: Of 10,713 surviving ARIC participants (age range, 69–88 years), we ascertained cognitive
diagnoses in 6471 in person, 1966 by telephone interviews (participant or informant), and the
remainder by medical record review. The prevalence of dementia was 9.0% and MCI 21%. Alz-
heimer’s disease (AD) was the primary or secondary etiology in 76% of dementia and 75% of
MCI participants. Cerebrovascular disease was the primary or secondary etiology in 46% of dementia
and 32% of MCI participants.
Discussion: MCI and dementia were common among survivors from the original ARIC cohort.
Nearly 30% of the ARIC cohort received diagnoses of either dementia or MCI, and for the majority
of these individuals, the etiologic basis was attributed to AD.
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The prevalence of dementia has been extensively studied
over the past 25 years [1]. Although there are fewer preva-
lence studies in African-Americans [2,3], those studies are
generally concordant with those from European or
European-American cohorts. Of the many prevalence
studies, only a few (Framingham [4], Honolulu [5]) recruited
persons at middle age and examined them in later life for de-
mentia. Among the major contributions of the investigationsimer’s Association. This is an open access article under the CC BY-NC-ND
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tance of midlife vascular risk factors and midlife cognition
for later life risks for cognitive impairment.
In 1987–1989, the Atherosclerosis Risk in Communities
(ARIC) study recruited a bi-racial group of 15,792 individ-
uals, ages of 45 and 64 years, from four US communities
in Maryland, North Carolina, Mississippi, and Minnesota.
Cognitive assessments were introduced in the second
ARIC examination in 1990–1992. A comprehensive
dementia surveillance was performed at the fifth ARIC ex-
amination, the Atherosclerosis Risk in Communities Neuro-
cognitive Study (ARIC-NCS), in 2011–2013. The goals of
ARIC-NCS were to study the relationships between midlife
health and later-life cognitive impairment. We report here on
the prevalence of clinical diagnoses of mild cognitive
impairment (MCI), dementia, and their attributed etiologies.
We also describe the methodological bases of ARIC-NCS to
facilitate future ARIC-NCS publications.Fig. 1. Timeline for participants in the ARIC-NCS. Abbreviations: ARIC-
NCS, Atherosclerosis Risk in Communities Neurocognitive study.2. Methods
2.1. Participants
The ARIC study was initiated in 1987. A random sample
of individuals between 45 and 64 years were recruited from
four communities: Washington County Maryland, Forsyth
County North Carolina, Jackson Mississippi, and suburban
Minneapolis Minnesota [6]. The overall goals of the ARIC
study were to assess the role of midlife cardiovascular risk
factors on health outcomes. An extensive cardiovascular ex-
amination was carried out at the initial visit (ARIC visit 1,
“v1”). From the beginning of the study in 1987, participants
were interviewed annually by phone, and discharge codes
were recorded for all reported hospitalizations and all hospi-
talizations occurring within ARIC communities.
At ARIC visit 2 (v2) in 1990–1992, all participants under-
went a 3-instrument cognitive assessment in addition to the
entire cardiovascular assessment [7]. The 3-instrument
cognitive testing was repeated in a subset of the ARIC cohort
who underwentmagnetic resonance imaging (MRI) in 1994–
1995; in the entire ARIC cohort at visit 4 (1996–1999) [8,9];
in a subset at the ARIC-MRI examination in 2004–2006
(Jackson and Forsyth County sites only); and again in the
full cohort at the latest visit (visit 5). ARIC participants had
APOE genotyping performed using the TaqMan assay
(Applied Biosystems, Foster City, CA) once that assay
became available. All surviving ARIC participants were
invited to an in-person assessment at ARIC-NCS visit 5 be-
tween June, 2011, and August, 2013. If they were unable or
unwilling to undergo an in-person assessment in clinic,
they were offered an in-person assessment in their home or
long-term care facility. If they were unwilling or unable to
participate in any in-person assessment, a telephonic cogni-
tive assessment was offered. If they were unable or unwilling
to unable to undergo a telephonic cognitive assessment, and
if cognitive impairment was suspected based on hospitaldischarge codes or annual telephone interviews, a family
member was invited to participate in an interview about the
participant’s cognitive and functional status. Fig. 1 shows
the flow of participants in ARIC.
Institutional review boards of each ARIC center have
approved the ARIC study protocol over its 28-year exis-
tence. Participants provided written informed consent for
their participation at each study visit. Consent was obtained
from a designated proxy along with the participant’s assent
in participants with a known diagnosis of dementia,
impaired mental status (determined in the examination), or
where our trained staff deemed that the participant had
diminished capacity to provide informed consent.
This work was funded by the US National Institutes of
Health who played no role in the preparation or final
approval of this article.2.2. Instruments
Participants who were evaluated in person at ARIC-NCS
underwent a sequential evaluation. The following cognitive,
behavioral, and functional assessments were completed for
all participants at ARIC-NCS.
2.2.1. Core in-person assessments
1. The centers for epidemiological studies-depression
scale [10] was administered. A score of .8 was
considered as suggestive of depression.
2. The three ARIC cognitive instruments that have been
administered beginning with ARIC visit 2 were the de-
layed word recall task, digit symbol substitution from
the Wechsler Adult Intelligence Scale -Revised
(WAIS-R), and a letter fluency task [7]. Normative
data [7,11] and longitudinal data [12,13] have been
presented.
D.S. Knopman et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2 (2016) 1-11 33. A neuropsychology test battery [11], logical memory
immediate and delayed recall, and incidental learning
from the Wechsler Memory Scale-III, trail making test
parts A and B, WAIS-R digits span backward, Boston
naming test, and animal naming. The mini-mental state
examination (MMSE) [14] was also administered.
Robust age, race, and education-specific normative
data for most of the measures in the battery were devel-
opedwithin ARIC [11]. Comparable normative data for
the Boston naming test and digit span backward were
derived from data obtained from the National Alz-
heimer’s Coordinating Center [15]. As previously re-
ported [16], we constructed Z-scores for each of four
cognitive domains (memory, psychomotor speed/exec-
utive functioning, language, and visuospatial) by aver-
aging the scores of tests within each domain,
subtracting the domain mean, and dividing by the
domain standard deviation. A global composite Z-score
was also derived from the three domain scores.2.2.2. More detailed in-person assessments in a subset
For those with complete or near complete data from the
mentioned in-person cognitive assessment, we used the
following rules to determine who would be invited for
more detailed assessments: (1) all participants who had un-
dergone an MRI in 2004–2006 as part of the ARIC-MRI
study; (2) all participants who had either (a) a low score
on MMSE (,21 for whites and ,19 for blacks) or (b)
who scored ,21.5 Z in any of five cognitive domains and
showed definite cognitive decline based on prior delayed
word recall task, digit symbol substitution from the
WAIS-R, and a letter fluency task scores administered at
prior ARIC visits (i.e., lowest 10 percentile on any test or
lowest 20th percentile on at least 2 tests); and (3) a random
10% sample of those who did not meet these criteria (i.e.,
those who were presumed cognitively normal).
1. Those invited to more detailed evaluations underwent
a neurologic examination performed by a study nurse
who had been trained by one of the study neurologists
(R.F.G.). The examination was used to complete a Na-
tional Institutes of Health stroke scale [17] and a
modified uniform Parkinson’s disease rating scale
(UPDRS) [18].
2. The informant and the participant underwent a clinical
dementia rating (CDR) interview. The CDR scale is a
multidimensional rating tool meant to assess severity
of impairment from cognitive normality to dementia
[19]. It consists of queries in six domains and uses
both participant and informant responses.
3. The informant completed the functional activities
questionnaire (FAQ), a 10-item instrument [20] that
surveys ability to perform 10 common daily activities.
4. The neuropsychiatric inventory (NPI) [21] was admin-
istered. It measures 12 neuropsychiatric symptom
complexes.5. A Hachinski ischemic score [22] was also completed
by the trained study personnel based on the history
and examination of the participant.
6. A focused neurologic history was also completed. It
included questions about events and symptoms that
could be linked to causes of dementia.
7. All participants who were evaluated in the second
stage who did not have contraindications were invited
to have a brain MRI.2.2.3. Assessment instruments for those not seen in person
For those not evaluated in person, but who agreed to a
telephone interview, a telephonic instrument of cognitive
status-modified (TICS-m) [23,24] was administered to
assess their cognition.
For those not evaluated in person and unable to undergo a
telephone interview, an informant interview was completed
primarily where therewas suspicion of cognitive impairment
or inadequate data to rule it out, more specifically if (1)
follow-up interviewer suspected cognitive impairment, (2)
follow-up interviewer reported hearing loss, (3) Interna-
tional Classification of Diseases, Ninth Revision (ICD-9) de-
mentia discharge code at any point since the start of cohort
surveillance, (4) self-report of dementia diagnosis on the
follow-up interview (starting January 1, 2012), (5) proxy
contacted for most recent follow-up interview, or if the
participant was part of (6) an age comparable random
sample of 100 participants not otherwise meeting the
mentioned criteria.
2.3. Magnetic resonance imaging
Brain MRI was performed for the dual purposes of ob-
taining quantitative imaging features for analysis and
supplementing the clinical etiologic diagnoses by document-
ing cerebrovascular lesions such as infarcts and white matter
hyperintensities. As previously detailed [16], all ARIC-NCS
participants selected for second-stage assessments without
contraindications were offered a brain MRI. The MRI scans
obtained were performed at each site on 3-T Siemens
(various models) scanners using a common set of sequences
that included a fluid-attenuated inversion recovery (FLAIR)
sequences. For the diagnostic purposes in this report, the
FLAIR scans were reviewed by both a neuroradiologist
and the clinical diagnostic adjudicators. The two lesions of
particular interest for a diagnosis of cerebrovascular etiology
of a cognitive disorder were white matter hyperintensities
and infarcts. Other structural abnormalities were also
considered as they arose.
2.4. Diagnoses of cognitive normality, MCI, or dementia
for participants undergoing in-person assessments
To standardize and describe the diagnoses of cognitively
normal, MCI, or dementia, we devised an algorithm as a
guide for diagnosis. The algorithm was based on the
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Institute on Aging–Alzheimer’s Association (NIA-AA)
workgroups [25,26] and Diagnostic and Statistical
Manual of Mental Disorders, 5th Edition (DSM-5) [27].
The algorithm used the following scores: MMSE, the
sum of the six individual domain ratings in the CDR
(“CDR sum of boxes”), z-scores from the current neuro-
psychological test battery, and change scores from the se-
rial 3-test ARIC cognitive assessments and the FAQ.
The algorithmic approach generated 37 possible combi-
nations of cognitive—functional profiles. The combinations
of cognitive and functional profiles were divided into those
that were internally consistent (concordant impression of
cognitive status) and those that were internally inconsistent
(discordant impressions of cognitive status). A listing of pro-
files is given in Appendix 1.
Concordant profiles for cognitive normality were defined
as not meeting criteria for MCI or dementia. Specifically, the
diagnosis of cognitive normality required that all
ARIC-NCS cognitive domain scores were better than
21.5 Z and that there was an absence of decline below the
10 percentile on one test or below the 20th percentile on
two tests in the serial ARIC cognitive battery. The CDR
sum of boxes (the sum of the six domain scores in the
CDR) was required to be 0.5 and the FAQ 5.
Concordant profiles for MCI were defined as at least one
domain score worse than21.5 Z, a CDR sum of boxes.0.5
and 3, an FAQ 5, and decline below the 10 percentile on
one test or below the 20th percentile on two tests in the serial
ARIC cognitive battery.
Concordant profiles for dementia were defined as .1
cognitive domain worse than 21.5 Z, a CDR sum of boxes
.3 and FAQ .5, and decline below the 10 percentile on
one test or below the 20th percentile on two tests in the serial
ARIC cognitive battery. In addition, a low MMSE score
(,21 for whites or ,19 for African-Americans), even in
the absence of more complete cognitive testing, was re-
garded as diagnostic of dementia.
Eight ARIC clinicians (four physicians: D.S.K., B.G.W.,
R.F.G., and Guy McKhann and four neuropsychologists:
M.S.A., T.H.M., L.C., and Ola Selnes) comprised an expert
dementia classification committee who reviewed materials
on the examinations that had been collected at each
ARIC site. One physician and one neuropsychologist inde-
pendently reviewed each participant whose algorithmic
profiles were concordant or discordant for MCI or demen-
tia. The reviewers then rendered syndromic and etiologic
diagnoses. A small number of profiles that were concordant
for cognitive normality were also reviewed. Preliminary
experience showed that participants whose algorithmic
diagnosis was “normal or suspected normal cognition”
were invariably viewed by the clinician reviewer panel as
normal, and subsequently only one reviewer was assigned
to review the data from those who were “normal or sus-
pected normal” by the algorithm. For individuals in
whom the two primary reviewers disagreed on cognitivesyndrome, primary etiology, or cerebrovascular disease
(CVD) etiology, a third reviewer (D.S.K. or M.S.A.) eval-
uated the participant’s case materials and rendered a
deciding vote.2.5. Diagnoses of dementia or not dementia among
participants not undergoing in-person assessments
For those ARIC participants who were alive at the time of
ARIC-NCS but who declined to be seen in person, we used
three strategies to establish diagnoses of dementia: the
TICSm score, an informant interview, and review of ICD-9
hospital discharge diagnostic codes.
A diagnosis of dementia based on TICSm scores was
made when the TICSm was 23. We adjusted for education
around this cut point in the following way: 5 points were
added to the score for those with ,eighth grade education,
2 points were added for those who completed grades 8–10,
and 2 points were subtracted for 41 years of college. We
did not use the TICSm to diagnose MCI, based on prior
experience [24]; hence, participants who were not demented
according to their TICSm scores were not considered in enu-
merations of MCI.
For those participants who did not complete either an in-
person assessment or a TICSm but who were alive at the
beginning of ARIC-NCS but had telephonic informant-
based assessments, we diagnosed dementia if the sum of
the informant ratings of the six domains of the CDR 3
and the FAQ.5. We did not attempt to diagnose MCI based
on informant interviews alone.
The ARIC study routinely collected ICD-9 discharge
diagnosis codes for all hospitalizations of as well as diag-
nostic codes from death certificates for all ARIC partici-
pants. These codes, available at the time of article
preparation through the year 2012, were used to diagnose de-
mentia for participants without other components of assess-
ment. The codes are given in Appendix 2. No attempt was
made to diagnose MCI using ICD-9 diagnostic codes.2.6. Summary of syndromic diagnostic procedures
There was one source for a diagnosis of MCI (the exam-
ination including full neuropsychological assessment and
CDR/FAQ/NPI). There were multiple sources for a dementia
diagnosis: (1) full neuropsychological assessment only; (2)
full neuropsychological assessment plus an FAQ, a CDR
interview, and an NPI interview; (3) TICSm only; (4) infor-
mant interviews using the CDR; and (5) hospital discharge
codes or diagnostic codes from death certificates.2.7. Etiologic diagnoses
Etiologic diagnoses were also assigned by the panel of
physicians and neuropsychologists, only for individuals
who were seen in person and who were given diagnoses of
MCI or dementia. The reviewers were allowed to diagnose
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one diagnosis as primary.
2.7.1. Alzheimer disease–related MCI/dementia
The diagnosis of Alzheimer’s disease (AD) as an etio-
logic diagnosis of MCI or dementia in ARIC as a primary
diagnosis is a clinical one and is based on the presence of
the cognitive syndrome that is not of abrupt onset and in-
cludes memory impairment and the absence of features of
other specific diagnoses sufficient to cause the cognitive
impairment, such as those detailed in the following. The
criteria from the NIA-AA workgroups [25,26] were
followed.
2.7.2. CVD-related MCI/dementia
The diagnosis of CVD as an etiology was defined by an
algorithm (Appendix 3) based in the National Institute of
Neurological Disorders and Stroke-Association Internatio-
nale pour la Recherche et l’Enseignement en Neurosciences
criteria [28] that used the following information: (1) history
of stroke regardless of temporal relationship to cognitive
decline; (2) history of stroke specifically temporally related
to an abrupt onset of the cognitive disorder as operational-
ized by an affirmative answer to the question: “Was the
cognitive impairment of abrupt onset following a stroke?”;
(3) bilateral or multiple infarcts or extensive white matter
hyperintensities on imaging; and (4) physical examination
evidence of a typical stroke pattern of neurologic signs. If
imaging was not available, a history of stroke and a history
of abrupt onset were considered sufficient to generate an
etiologic diagnosis of CVD-related cognitive impairment.
2.7.3. Lewy body disease–related MCI/dementia
A diagnosis of Lewy body disease (LBD) as a primary
etiologic diagnosis was made based on published criteria
[29,30] when there were at least two of the following: (1)
Parkinson’s disease (diagnosed as per the history or
suggested by the UPDRS; or on anti-Parkinson medica-
tions), (2) history of fluctuations in alertness or cognition,
(3) dream enactment behavior reported by an informant, or
(4) hallucinations. If only one of the features was present,
the diagnosis of LBD could be applied only as a secondary
diagnosis.
2.7.4. Other diagnoses
Other diagnoses are listed in Appendix 4 but will not be
discussed in this report.2.8. Analyses
Distribution of demographic characteristics is presented
by assessment type and diagnosis. For participants with mul-
tiple assessments, the most reliable assessment type was re-
ported, i.e., reviewer diagnosis was preferred over
algorithmic diagnosis among those participants assessed in
person, an in-person diagnosis was preferred over theTICSm and all assessments (including informant interview)
were preferred over surveillance data. Continuous and cate-
gorical variables were presented as means (standard devia-
tions) and percentages, respectively.
Diagnostic results were compared in participants with
multiple assessment types: reviewer versus algorithmic
diagnosis and TICSm versus in-person diagnosis. Combined
assessments were compared with surveillance of hospitali-
zations and deaths. Sensitivity, specificity, positive predic-
tive value (PPV), and negative predictive value (NPV)
with 95% confidence intervals (CIs) were calculated treating
the more reliable assessment as the gold standard.
Age-, race-, and sex-specific prevalence of MCI were re-
ported for those ARIC participants who were seen in person.
Baseline-category logit models were used to test hypotheses
that the prevalence of MCI would rise with advancing age,
would be similar in men and women, and would be greater
in African-Americans than whites, controlling for age group,
sex, and race. Age group-, race-, and sex-specific prevalence
of dementia are reported for all ARIC participants alive at
the start of ARIC-NCS. Logistic regression models were
used to test similar hypotheses. Analyses were performed
in SAS 9.3 (SAS Institute, Cary, NC, USA).
Distributions of etiologic diagnoses were compared
between MCI and dementia diagnoses using a Pearson c2
test.3. Results
Table 1 lists the demographic characteristics of the incep-
tion cohort from ARIC v1 in 1987–1989 according to their
vital status and assessment type at the time of ARIC-NCS
in 2011–2013, and Fig. 1 shows the history before 2011 of
the ARIC cohort. Forty-one percent (n5 6471) of the incep-
tion cohort were examined in person in ARIC-NCS. MRI
scans were usable in 1906. Some information on cognitive
status was available on another 3743 individuals through
either TICSm (n 5 1461), an informant interview
(n 5 505), or information from hospital discharge or death
codes recorded during the time frame of ARIC-NCS
(n5 1777). An additional 499 participants were not assessed
and had no reported hospitalizations or death. Nearly one-
third (n5 5031, 32%) of ARIC participants in the inception
cohort had died before ARIC-NCS. The incidence of demen-
tia among the decedents will be reported separately. Higher
age at baseline and lower educational attainment character-
ized those whowere deceased, or who, by virtue of suspicion
of cognitive impairment, were assessed by informant tele-
phonic interview or had at least one hospitalization during
the period covered by ARIC-NCS. Lower ARIC v2 test
scores from the ARIC serial test battery were observed in
those who had died or who were assessed by informant tele-
phone interview.
Demographic characteristics by MCI and dementia diag-
nosis are presented in Table 2 according to the assessment
method. Among those evaluated in-person, the expected
Table 1
Demographic characteristics of ARIC inception cohort participants by vital status and assessment type
Characteristic
Deceased
before NCS
Completed NCS
in-person assessment
TICS-m
assessment
Informant
call assessment
At least one
hospitalization
or death
No diagnostically
useful information
n 5031 6471 1461 505 1777 499
% Women 45 59 66 59 58 62
% African-American 33 24 24 29 26 27
Age at visit 5* — 75.3 (5.2) 76.7 (5.6) 79.6 (5.7) 77.9 (5.7) 75.5 (5.5)
Age at visit 1* 56.9 (5.5) 52.1 (5.2) 53.4 (5.5) 56.3 (5.6) 54.7 (5.7) 52.4 (5.4)
, High school education, % 34 15 19 36 27 20
High School graduate or equivalent, % 38 42 47 33 41 44
1-y college, % 28 43 33 30 32 35
APOE ε4: one allele, % 30 27 26 36 29 27
Two alleles, % 3 2 2 5 3 2
V2 DWRT Z-score* 20.29 (1.04) 0.17 (0.95) 0.12 (0.98) 20.14 (0.93) 20.04 (0.98) 0.13 (0.94)
V2 DSST Z-score* 20.39 (1.01) 0.25 (0.95) 0.12 (0.92) 20.28 (0.98) 20.06 (0.92) 0.16 (0.96)
V2 WFT Z-score* 20.19 (1.03) 0.15 (0.98) 0.02 (0.96) 20.11 (1.04) 20.09 (0.95) 0.03 (0.99)
Abbreviations: ARIC, Atherosclerosis Risk in Communities study; TICS-m, telephonic instrument of cognitive status-modified; APOE, apolipoprotein E.
NOTE. Data are missing for the following covariates: education (n5 26); APOE ε4 (n5 680); DWRT (n5 1582); DSST (n5 1632); and WFT (n5 1602).
The columns are mutually exclusive and hierarchically defined.
*Mean (standard deviation).
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an apolipoprotein E (APOE) ε4 allele, and lower scores on
ARIC v2 cognitive testing were observed in those with de-
mentia. These relationships were not as strong in personsTable 2
Distribution of participant characteristics by assessment type and diagnosis; ARIC
Characteristic
Completed ARIC-NCS in-person
assessment (n 5 6471)
T
(n
Normal MCI Dementia N
Overall 4743 1371 342 1
Gender
Male 1858 (39)* 651 (47) 147 (43)
Female 2885 (61) 720 (53) 195 (57)
Race
White 3647 (77) 1080 (79) 199 (58) 1
Black 1096 (23) 291 (21) 143 (42)
Education
, High School education 647 (14) 193 (14) 130 (38)
High School grad or equivalent 1962 (41) 610 (44) 114 (34)
1-y college 2125 (45) 568 (41) 96 (28)
APOE ε4
0 3326 (73) 894 (68) 168 (52)
1 1228 (27) 417 (32) 156 (48)
V2 DWRT Z-score
,21.0 607 (13) 277 (20) 118 (35)
21.0 to ,0 951 (21) 364 (27) 71 (21)
0 3044 (66) 712 (53) 145 (43)
V2 DSST Z-score
,21.0 391 (9) 169 (12) 109 (33)
21.0 to ,0 1043 (23) 485 (36) 115 (35)
0 3165 (69) 699 (52) 107 (32)
V2 WFT Z-score
,21.0 423 (9) 224 (17) 82 (25)
21.0 to ,0 1527 (33) 543 (40) 133 (40)
0 2652 (58) 586 (43) 116 (35)
Abbreviations: ARIC-NCS, Atherosclerosis Risk in Communities Neurocognitiv
cognitive status-modified; APOE, apolipoprotein E.
*Number (column-wise percent). The columns are mutually exclusive and hierwith dementia identified through means other than in-
person assessment, probably reflecting the reasons that an
in-person assessment was not completed and greater diag-
nostic uncertainty.-NCS study
ICS-m assessment
5 1461)
Informant call
assessment (n 5 505)
Surveillance
(n 5 2276)
ormal Dementia Normal Dementia Normal Dementia
361 100 169 336 2089 187
468 (34) 33 (33) 79 (47) 127 (38) 866 (41) 69 (37)
893 (66) 67 (67) 90 (53) 209 (62) 1223 (59) 118 (63)
070 (79) 44 (44) 113 (67) 247 (74) 1551 (74) 129 (69)
291 (21) 56 (56) 56 (33) 89 (26) 538 (26) 58 (31)
240 (18) 40 (40) 69 (41) 114 (34) 521 (25) 62 (33)
650 (48) 41 (41) 49 (29) 119 (35) 877 (42) 75 (40)
469 (35) 19 (19) 51 (30) 103 (31) 687 (33) 49 (26)
949 (73) 68 (69) 114 (72) 173 (53) 1413 (70) 97 (53)
354 (27) 30 (31) 45 (28) 152 (47) 594 (30) 85 (47)
212 (17) 32 (38) 36 (24) 79 (25) 386 (22) 47 (27)
297 (24) 20 (24) 48 (32) 81 (26) 411 (23) 39 (23)
748 (60) 32 (38) 66 (44) 156 (49) 981 (55) 85 (50)
137 (11) 35 (42) 38 (25) 73 (23) 270 (15) 40 (24)
365 (29) 25 (30) 60 (40) 119 (38) 591 (33) 61 (36)
753 (60) 23 (28) 52 (35) 124 (39) 915 (52) 69 (41)
152 (12) 32 (39) 34 (23) 46 (15) 281 (16) 31 (18)
479 (38) 35 (42) 67 (45) 128 (41) 712 (40) 64 (37)
625 (50) 16 (19) 47 (32) 142 (45) 782 (44) 76 (44)
e study; MCI, mild cognitive impairment; TICS-m, telephonic instrument of
archically defined.
Table 3
Mild cognitive impairment prevalence by race, sex, and age group
Group 65–69 70–74 75–79 80–84 85–89 Total
Total n 1150 2261 1681 1065 314 6471
All, %
Male 15 24 27 28 34 24
Female 11 16 22 27 29 19
Total 13 19 24 27 31 21
White, %
Male 16 25 28 29 36 26
Female 11 16 21 27 33 19
Total 13 20 24 28 34 22
Black, %
Male 13 21 21 23 22 19
Female 12 16 25 27 19 19
Total 12 18 24 25 20 19
Abbreviation: ARIC-NCS, Atherosclerosis Risk in Communities Neuro-
cognitive study.
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diagnosis and final adjudicated diagnoses
Among participants evaluated in person, algorithmic di-
agnoses were compared with the opinion of the clinician
reviewers. The clinician reviewers agreed with the algo-
rithmic diagnosis of dementia in 275 of 293 (94%) persons.
The clinician reviewers disagreed in 14 persons with an
algorithmic diagnosis of dementia, assigning 13 a diagnosis
of MCI and one a diagnosis of cognitively normal. In four
instances, the clinician reviewers did not have enough infor-
mation to make a syndromic diagnosis. For algorithmic di-
agnoses of MCI, the clinician reviewers disagreed with the
algorithm in 9% (111 of 1220). When they disagreed, they
were more likely to diagnose cognitive normality (62%, 69
of 111) than dementia (34%, 38 of 111). The reviewers
were unable to arrive at a diagnosis in four participants.NOTE. P values for Wald tests of main effects adjusted for other covari-
ates: gender P , .0001; race P 5 .9139; age P , .0001; Wald test of the
race! gender interaction was marginally significant (P5 .0497). Estimates
based on participants evaluated in person at ARIC-NCS.3.2. Validity of TICSm diagnoses of dementia versus
in-person assessments
There were 248 participants who underwent both an in-
person assessment and a TICSm. Dementia was diagnosed
in person in 22 of them (8.8%). At a cut score of 23, the
TICSmhad a sensitivity of 50% (95%CI, 28%–72%), a spec-
ificity of 94% (95% CI, 90%–97%), a PPVof 44% (95% CI,
24%–65%), and an NPV of 95% (95% CI, 91%–98%).
Because the cut score of 23 was selected by the investigators
to achieve greater diagnostic specificity in the group assessed
only by interview, the lower sensitivity was anticipated.Table 4
Dementia prevalence by race, sex, and age group
Group 65–69 70–74 75–79 80–84 85–89 Total
Total n 1642 3383 2777 2096 815 10,713
All, %
Male 3.2 4.8 7.5 15 24 8.7
Female 2.4 4.3 9.7 15 26 9.2
Total 2.7 4.5 8.8 15 25 9.0
White, %
Male 2.6 3.4 5.1 14 22 7.6
Female 1.9 3.0 7.5 13 22 7.7
Total 2.2 3.2 6.5 14 22 7.73.3. Validity of hospital/death code diagnoses of dementia
versus in-person assessments
Across all methods of ascertainment (in person, TICSm,
and telephonic informant interviews), there were 8437 as-
sessments with 778 dementia diagnoses among them. The
sensitivity of hospital and death diagnostic codes for demen-
tia was 25% (95% CI, 22%–29%) and the specificity 99%
(95% CI, 99%–99%). The PPV of the hospital/death codes
was 70% (95% CI, 64%–75%) and NPV was 93% (95%
CI, 92%–93%). However, if analyses were restricted to those
participants with a hospitalization or death within 1 year of
an in-person diagnosis, TICSm assessment, or informant
telephone interview, sensitivity rose to 67% (95% CI,
62%–73%) and PPV to 82% (95% CI, 76%–86%), whereas
specificity (97%; 95% CI, 96%–98%) and NPV (94%; 95%
CI, 92%–95%) changed very little.Black, %
Male 4.7 9.8 18 19 33 13
Female 3.3 7.4 16 22 40 13
Total 3.7 8.2 16 21 38 13
Abbreviation: ARIC-NCS, Atherosclerosis Risk in Communities Neuro-
cognitive study.
NOTE. P values for Wald tests of main effects adjusted for other covari-
ates: gender P 5 .903; race P , .0001; age P , .0001; Wald test of the
race! gender interaction was not significant (P 5 .461). Estimates based
on all participants alive at the start of ARIC-NCS.3.4. Age-, sex-, and race-specific prevalence of MCI and
dementia
Table 3 presents age-, race-, and sex-specific prevalences
of MCI based on in-person assessments. Table 4 presents
age-, race-, and sex-specific prevalences of dementia based
on participants alive at the start of ARIC-NCS. As expected,
prevalence of both MCI and dementia increased withadvancing age (P , .001 for both). Prevalence of MCI was
higher in men than women (24% vs. 19%, P , .001). Prev-
alence of dementia was higher in women overall versus men
(9.2% vs. 8.7%) but was not statistically significant
(P 5 .09). In the 65–69 year age bracket, less than 16% of
ARIC survivors were considered to have cognitive impair-
ment (i.e., either MCI or dementia), whereas in the oldest
age bracket, over half were cognitively impaired, although
most had MCI, not dementia. Dementia was more prevalent
in blacks than whites (P , .001), whereas there were no
racial differences for MCI prevalence.
3.5. Etiology-specific diagnoses in MCI and dementia
Among the participants examined in person, the assigned
etiologies for those diagnosed with MCI or dementia are
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etiologies (58%) of dementia and the highest proportion as
either a primary or secondary etiology (76%). CVD as a pri-
mary etiology of dementia made up 24% and as a primary or
secondary diagnosis in 46%. LBD was rare as a primary eti-
ology (5%) but was more common as a secondary etiology
for dementia (12%, 43 of 342). The majority (58%) of de-
mentia cases received more than one etiologic diagnosis,
with the combination of AD and CVD most common
(n 5 141, 41%).
Etiologic diagnoses in MCI were more weighted toward
AD as a primary one (66%), with proportionately fewer as-
signed a primary etiology of CVD (10%) and fewer given
more than one etiologic diagnosis (47%, 647 of 1371). AD
as a primary or secondary etiologic diagnosis was about
the same proportion in MCI as in dementia (75% vs. 76%,
c25 0.49, P5 .48), but CVD as a primary or secondary etio-
logic diagnosis was less frequent in MCI (32%) compared
with dementia (32% vs. 46%, c25 25.8, P, .001). Overall,
more MCI participants were assigned a single etiology of
AD, CVD, or LBD compared with the dementia participants
(33% vs. 25%, c2 5 7.5, P 5 .006).4. Discussion
The purpose of this report was to show prevalence data in
the well-described ARIC cohort and describe the method
used to diagnose MCI and dementia in participants alive at
the start of ARIC-NCS. Although nearly one-third of theTable 5
Etiologic diagnoses by syndrome in participants examined in person; ARIC-
NCS
Etiology
Syndromic diagnoses
TotalMCI, n (%) Dementia, n (%)
Pure AD 427 (31) 73 (21) 500
AD with CVD 302 (22) 78 (23) 380
AD with LBD 100 (7) 33 (10) 133
AD with other 82 (6) 14 (4) 96
AD primary 911 (66) 198 (58) 1109
AD primary or secondary 1021 (75) 261 (76) 1282
Pure CVD 14 (1) 8 (2) 22
CVD with AD 110 (8) 63 (18) 174*
CVD with LBD 9 (1) 10 (3) 19
CVD with other 2 (0) 0 (0) 2
CVD primary 135 (10) 81 (24) 216
CVD primary or secondary 437 (32) 159 (46) 596
Pure LBD 5 (0) 4 (1) 9
LBD with other 42 (3) 13 (4) 55
LBD primary 47 (3) 17 (5) 64
LBD primary or secondary 156 (11) 60 (18) 216
Other 22 (2) 2 (1) 24
Insufficient information 256 (19) 44 (13) 306y
Total 1371 342 1720
Abbreviations: ARIC-NCS, Atherosclerosis Risk in Communities Neuro-
cognitive study; AD, Alzheimer’s disease; MCI, mild cognitive impairment;
CVD, cerebrovascular disease; LBD, Lewy body disease.
*One case of uncertain cognitive syndrome excluded.
ySix cases of uncertain cognitive syndrome excluded.inception cohort had died, we examined in person nearly
two-thirds of survivors. The prevalence of dementia in
ARIC-NCS was in line with prior reports [1,31]. The
prevalence of MCI in ARIC-NCS was also comparable
with other groups [32–34]. Although there were race and
sex differences in MCI and dementia prevalence, these
differences were dwarfed by the powerful effect of age on
cognitive impairment. Using recent formulations for
etiologic diagnoses using clinical or clinical and MRI, AD
was the dominant etiology for both MCI and dementia
while CVD was also common. Even with the imprecision
inherent in etiologic diagnoses made with limited
information, cognitive impairment attributed to more than
one etiology occurred in more than half the cases. As
expected, participants with dementia were more likely to
have more than one etiology compared with MCI.
The prevalence of cognitive impairment at one point in
time underestimates the lifetime burden of disease because
of differential survival from middle age. With extensive car-
diovascular and cognitive evaluations over the long history
of ARIC as well as knowledge of what happened to members
of the ARIC cohort who were no longer alive at ARIC-NCS
in 2011–2013, we are in a position of depicting the complex
interplay of cognition, cardiovascular health, cerebrovascu-
lar health, and mortality from middle age into the eighth
decade of life in a longitudinal cohort. The current analysis
is the foundation for subsequent reports that will go into
detail about these relationships.
The prevalence of dementia in ARIC-NCS cohort among
those evaluated in person was lower than prior reports [1,31],
but when all sources of information were used, the overall
prevalence of dementia in living ARIC participants
corresponded closely to estimates from the literature
[1,31]. By simultaneously accounting for MCI prevalence
as well, we present a comprehensive view of cognitive
functioning in a large representative cohort. The fact that
nearly as many patients with dementia were identified by
informant interview as by in-person examinations demon-
strates the tendency of persons with dementia to decline
participation in observational studies [35]. Had those whose
informants were contacted by phone not had a prior relation-
ship with ARIC, it is doubtful that we would have been able
to obtain any information about the 505 persons who were
alive at the time of ARIC-NCS but unable or unwilling to
come for an in-person assessment. Use of the TICSm assess-
ments and the hospital/death codes identified additional de-
mentia cases, albeit with imperfect sensitivity, but those
other surveillance methods allowed us to include more cases
defined with high specificity in future analyses of midlife
risk factors.
MCI was prevalent in ARIC-NCS, and the prevalence of
MCI was similar to other recent studies [32,33]. Had MCI
been detectable by telephonic means, it might have
included an even larger number of individuals, but
currently only in-person techniques can be used to diagnose
MCI. Because different MCI definitions result in marked
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cisely our findings to other studies. We used consensus
normative cut points to base diagnoses of MCI or dementia
[25–27], but operational variations across studies is
inevitable. Longitudinal studies of incident dementia in
this cohort are necessary to provide validation for our MCI
definitions.
There were differences between blacks and whites in the
prevalence of dementia, with blacks generally having higher
rates. There were no racial differences in prevalence of MCI.
Some prior studies report higher rates of MCI and dementia
in blacks [36–39], but other studies found no differences
between blacks and whites [40]. However, differences
observed need to be placed in the context of the higher mor-
tality in blacks before evaluation. The advantage of
ARIC-NCS over others that have examined dementia preva-
lence in African-Americans is that members of both races
were evaluated simultaneously using the same methods.
Note that the methods used different adjustments for blacks
and whites, based on normative data from well-defined
normative subsamples of black and white participants in
prior ARIC studies.
In contrast to some studies [1,31,41] but not others
[38,40,42], there were no consistent differences in
dementia prevalence between men and women, but men
were consistently more likely to receive a diagnosis of
MCI [32]. We accept the view that men are probably at
greater risk for cognitive impairment, but because of their
premature mortality, the number of prevalent cases in
women eventually exceeds that in men [4].
We made etiologic diagnoses for those with cognitive
disorders, relying on the informant interviews, neurologic
examinations, neuropsychological test result patterns, and
imaging in a majority, including nearly all with impairments.
We recognize that etiologic diagnoses in epidemiologic
contexts are subject to uncertainty. In the absence of
amyloid imaging, 18Fluorodeoxyglucose Positron Emission
Tomography, or cerebrospinal fluid biomarkers of AD, the
etiologic diagnosis of AD in ARIC-NCS was based on a
combination of a multidomain amnestic disorder in the
absence of convincing evidence of an alternative primary eti-
ology. Thus, a diagnosis of AD as an etiology in a setting
such as ARIC-NCS will be imprecise. We used an algo-
rithmic approach to the diagnosis of LBD and CVD, but it
is well known that the individual features on which those
two diagnoses of LBD [30] and CVD [43] are based are
neither sensitive nor specific. With the caveat that we cannot
attribute causality by mere presence alone, it is remarkable
that CVD features were present in nearly one in four persons
with dementia similar to prior epidemiologic [5,31] and
neuropathologic reports [44–46]. In MCI, only one in 10
had CVD features; we are not aware of other studies that
quantified etiologic features in MCI.
Strengths of our study include the 251 year history of the
participants in ARIC, our comprehensive in-person assess-
ments, and the availability of imaging to supplement diagno-ses in those with cognitive impairments, representing nearly
one-third of the total examined. We used state-of-the-art
diagnostic approaches that allow us to deconstruct diagno-
ses, both syndromic and etiologic, which improved transpar-
ency of the relationship between raw data from participants
and ultimate diagnoses. We used state-of-the-art diagnostic
criteria that were operationally defined in advance. Double
review by neurologists or a geriatrician and neuropsycholo-
gists with adjudication was also strength; as was the devel-
opment and use of a clinically derived algorithmic
approach to diagnosis. Although the algorithm was meant
to reduce between-clinician variation, a clinician could over-
ride the algorithmic diagnosis if the data justified it. The al-
gorithm was helpful in the frequent instances where clinical
information was internally discordant (i.e., very low cogni-
tive assessment scores in the face of an informant-derived
FAQ or CDR indicating no dysfunction). We are not aware
of any published strategies to deal with such occurrences.
Furthermore, ARIC-NCS had access to the 25-year record
of hospitalizations among participants, as well as the rapport
built up over that time that enabled us to perform telephonic
assessment of cognition or informant interviews among
those who were no longer able to come for an in-person
assessment.
Weaknesses are ones that are inherent in epidemiologic
surveys. There were many nonparticipants, although we
were able to account for them, and in most cases document
their status at the time of ARIC-NCS. Our diagnostic
methods were not as thorough as might be done in clinical
practice or in focused research settings such as dementia
clinical trials. Diagnoses were made by review of case report
forms, not by the direct interview and observation by our
diagnostic reviewers. Nuances from the neurologic examina-
tion or from face-to-face interviews were, thus, not acces-
sible to our diagnosticians. However, independent reviews
by two skilled clinicians for each participant and additional
reviews or committee discussions were required for adjudi-
cation among disagreements, all of which enhanced the di-
agnoses in this cohort setting.Acknowledgments
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1. Systematic Review: We searched PubMed for En-
glish-language publications on the prevalence and
incidence of mild cognitive impairment or dementia.
We cited several specific publications [1–5, 31–42].
2. Interpretation: The Atherosclerosis Risk in Commu-
nities (ARIC) Study was initiated in 1987 to study
outcomes of cardiovascular and cerebrovascular dis-
eases. Beginning with the second ARIC study visit,
cognition was also assessed. In 2011-2013, the
ARIC Neurocognitive Study performed both in-per-
son, telephonic and medical record reviews to diag-
nose prevalent mild cognitive impairment and
dementia. Here we describe the ascertainment meth-
odology of the ARIC Neurocognitive Study. We pro-
vide prevalence estimates and presumed etiologies
for both mild cognitive impairment and dementia.
The current report replicates prevalence values for
MCI and dementia from other populations.
3. Future Directions: The description of the methodol-
ogy and of the prevalence estimates provided here
will serve as the basis for future reports from the
ARIC Neurocognitive Study. The ARIC study is
unique because of its ability to link mid-life cardio-
vascular and cognitive status to late-life cognitive
disorders. The ARIC is also able to account for those
lost to follow-up.
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